Why a consulting firm focused life sciences bought a healthcare crowdsourcing platform
Alira Health hopes its purchase of RedCrow will help it stand out from the crowd of consulting firms that help life sciences companies bring drugs to market.
Covid-19 vaccines & therapies helped push medicines spending to $407B in 2021
While Covid-19 has had a significant impact on drug spending, IQVIA projects that its effect will moderate in coming years. IQVIA’s new report on U.S. medicines spending projects that immunology, oncology, and neurology will continue to drive the growth in drug spending.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
IQVIA report: Drug R&D reaches new highs, and not just for Covid-19 products
The biopharmaceutical industry continues to be a hotbed of activity, with more than 6,000 products in active development and a growing share of that innovation coming from new geographic regions. The findings are from a new industry report from IQVIA.
Report: Digital health tools maturing as research, funding grows
Consumers and benefits managers have a record number of digital health tools to choose from, according to a new report by the IQVIA Institute for Human Data Science.
Data companies band together to form RWE Alliance
Can an industry coalition help craft policy to support the use of Real-World Evidence? Five prominent real-world data and analytics companies are betting on it, launching the RWE Alliance.
IQVIA adds to growing lab biz with $198M deal for Myriad contract services unit
IQVIA is paying nearly $200 million to purchase a Myriad Genetics subsidiary that provides pharmaceutical contract services, a deal that will put the new acquisition in the company's Q2 Solutions unit. The deal follows IQVIA's April announcement that it had secured full ownership of Q2, which had been a joint venture with Quest Diagnostics.
presented by
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Covid-19 serves as catalyst for effort to diversify clinical trial enrollment
Covid-19 showed how technology can upend the old ways of clinical trials. Panelists at MedCity's INVEST conference said it's highlighting the importance of improving clinical trial diversity so that tests of new therapies and vaccines reflect the population of patients that they will treat in the real world.
IQVIA pays Quest Diagnostics $760M to get full control of central lab joint venture
IQVIA has acquired Quest Diagnostics’ minority stake in Q2 Solutions, a central laboratory services joint venture the two companies formed in 2015. But Quest will remain a preferred provider of lab testing services under an agreement with Q2.
IQVIA creates online Covid-19 clinical trial matching system
The website is designed to use the life sciences data analytics firm's own technology and algorithms, along with publicly available trial information, to match patients and physicians with clinical trials of treatments and vaccines for the disease.
Startup raises $6M to make it easier to fill specialty scripts
HelpAround raised $6 million in funding from IQVIA and Windham Ventures. The company’s software is designed to make it easier for patients to navigate specialty prescriptions.
Maximize Revenue and Patient Care with Strategic Weight Loss Management
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Nearly three-quarters of late-stage pipeline drugs come from emerging biopharma, report finds
The report, from IQVIA, stated that growth in the number of registration studies with active controls indicates payers' increasing interest in comparative-effectiveness data.
Survey highlights drugmakers’ CRO needs as demand for services grows
The report, by CRO Worldwide Clinical Trials, shows growing need for early-stage development expertise, with high demand for data quality, efficiency and overall trial management.
Global CRO market to grow to $57 billion by 2024, report forecasts
Growth in the CRO sector is expected to accompany growth of clinical trials, their complexity and regulatory requirements.
New report offers good news on drug spending, opioid prescriptions
The use of coupons and manufacturer buydowns is increasing as a way to offset what would otherwise be increasing costs borne by the patients, according to Murray Aitken, senior vice president and executive director of the IQVIA Institute for Human Data Science,